These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 19794285

  • 1. Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome.
    Tauchmanova L, Guerra E, Pivonello R, De Martino MC, De Leo M, Caggiano F, Lombardi G, Colao A.
    J Endocrinol Invest; 2009 May; 32(5):390-4. PubMed ID: 19794285
    [Abstract] [Full Text] [Related]

  • 2. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
    Muratore M, Quarta L, Calcagnile F, Quarta E.
    Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
    [Abstract] [Full Text] [Related]

  • 3. Fracture risk and bone health in adrenal adenomas with mild autonomous cortisol secretion/subclinical hypercortisolism: a systematic review, meta-analysis and meta-regression.
    Pal R, Banerjee M, Prasad TN, Walia R, Bhadada T, Singh J, Bhadada SK.
    J Bone Miner Res; 2024 Aug 05; 39(7):885-897. PubMed ID: 38703381
    [Abstract] [Full Text] [Related]

  • 4. Improved efficacy of intramuscular weekly administration of clodronate 200 mg (100 mg twice weekly) compared with 100 mg (once weekly) for increasing bone mineral density in postmenopausal osteoporosis.
    Frediani B, Bertoldi I, Pierguidi S, Nicosia A, Picerno V, Filippou G, Cantarini L, Galeazzi M.
    Clin Drug Investig; 2013 Mar 05; 33(3):193-8. PubMed ID: 23456672
    [Abstract] [Full Text] [Related]

  • 5. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB, Noyan V, Yildiz A, Biberoğlu K.
    Climacteric; 2000 Jun 05; 3(2):92-101. PubMed ID: 11910657
    [Abstract] [Full Text] [Related]

  • 6. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K, Probone Study Group.
    Osteoporos Int; 2002 Dec 05; 13(12):937-47. PubMed ID: 12459936
    [Abstract] [Full Text] [Related]

  • 7. Effects of two administration schemes of intramuscular clodronic acid on bone mineral density: a randomized, open-label, parallel-group study.
    Frediani B.
    Clin Drug Investig; 2011 Dec 05; 31(1):43-50. PubMed ID: 20932069
    [Abstract] [Full Text] [Related]

  • 8. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.
    J Bone Miner Res; 2004 May 05; 19(5):728-36. PubMed ID: 15068495
    [Abstract] [Full Text] [Related]

  • 9. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
    Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ.
    J Bone Miner Res; 2004 Aug 05; 19(8):1221-30. PubMed ID: 15231008
    [Abstract] [Full Text] [Related]

  • 10. Assessment of non-traumatic vertebral fractures in Cushing's syndrome patients.
    Apaydın T, Yavuz DG.
    J Endocrinol Invest; 2021 Aug 05; 44(8):1767-1773. PubMed ID: 33420960
    [Abstract] [Full Text] [Related]

  • 11. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound.
    Frediani B, Falsetti P, Baldi F, Acciai C, Filippou G, Marcolongo R.
    Bone; 2003 Oct 05; 33(4):575-81. PubMed ID: 14555261
    [Abstract] [Full Text] [Related]

  • 12. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome.
    Minetto M, Reimondo G, Osella G, Ventura M, Angeli A, Terzolo M.
    Osteoporos Int; 2004 Nov 05; 15(11):855-61. PubMed ID: 15034643
    [Abstract] [Full Text] [Related]

  • 13. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY, Lecart MP, Richy F.
    J Rheumatol Suppl; 2005 Sep 05; 76():21-5. PubMed ID: 16142847
    [Abstract] [Full Text] [Related]

  • 14. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status.
    Tauchmanovà L, Pivonello R, Di Somma C, Rossi R, De Martino MC, Camera L, Klain M, Salvatore M, Lombardi G, Colao A.
    J Clin Endocrinol Metab; 2006 May 05; 91(5):1779-84. PubMed ID: 16522701
    [Abstract] [Full Text] [Related]

  • 15. Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism.
    Tauchmanovà L, Pivonello R, De Martino MC, Rusciano A, De Leo M, Ruosi C, Mainolfi C, Lombardi G, Salvatore M, Colao A.
    Eur J Endocrinol; 2007 Sep 05; 157(3):359-66. PubMed ID: 17766720
    [Abstract] [Full Text] [Related]

  • 16. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ, Naganathan V, Barton I, Grauer A.
    J Bone Miner Res; 2004 Feb 05; 19(2):323-9. PubMed ID: 14969403
    [Abstract] [Full Text] [Related]

  • 17. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 05; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 18. Intramuscular clodronate therapy in postmenopausal osteoporosis.
    Rossini M, Braga V, Gatti D, Gerardi D, Zamberlan N, Adami S.
    Bone; 1999 Feb 05; 24(2):125-9. PubMed ID: 9951781
    [Abstract] [Full Text] [Related]

  • 19. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
    Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T.
    Osteoporos Int; 2009 Aug 05; 20(8):1429-37. PubMed ID: 19101754
    [Abstract] [Full Text] [Related]

  • 20. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
    Gutteridge DH, Stewart GO, Prince RL, Price RI, Retallack RW, Dhaliwal SS, Stuckey BG, Drury P, Jones CE, Faulkner DL, Kent GN, Bhagat CI, Nicholson GC, Jamrozik K.
    Osteoporos Int; 2002 Aug 05; 13(2):158-70. PubMed ID: 11908491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.